#Oncoalert

Смотрите Reels видео о Oncoalert от людей со всего мира.

Смотрите анонимно без входа.

Трендовые Reels

(12)
#Oncoalert Reel by @oncoalert - 🌐 Big news: The 6th OncoAlert 🚨Colloquium is NOW AVAILABLE IN YOUR LANGUAGE!! ALL VIDEOS HERE 👇👇https://oncoalert360.com/multi-language127760coll
959
ON
@oncoalert
🌐 Big news: The 6th OncoAlert 🚨Colloquium is NOW AVAILABLE IN YOUR LANGUAGE!! ALL VIDEOS HERE 👇👇https://oncoalert360.com/multi-language127760colloquium.html 🇪🇸🇮🇳🇵🇹🇮🇹🇫🇷🇺🇦🇯🇵🇲🇽🇸🇦🇷🇺and many more SPOKEN & WITH CAPTIONS in 1⃣8⃣Languages Top oncology experts. Global reach. Zero barriers. Watch the 50-sec video to learn how!! @elisabetta_bonzano @eli_agoss @drjosefernandomoura @natalia.gandur @kristina_jankovic @matteo.lambertini @evandretto @esgo.society @agz_eriksson @_i_c_r_o_ @essonews @barbaramelao_urologia @lucarecco @ENYGO @nico.bizza @aleksandra_strojna @gerry.hanna @fadihaddadmd @_i_c_r_o_ @drsgraff
#Oncoalert Reel by @oncoalert - The OncoAlert🚨Newsletter Covering March 20-26, 2026 REGISTER TO GET IT 👉 https://buff.ly/7Jlzp0V or www.OncoAlert360.com 🚨 This week's Spotlight
3.5K
ON
@oncoalert
The OncoAlert🚨Newsletter Covering March 20-26, 2026 REGISTER TO GET IT 👉 https://buff.ly/7Jlzp0V or www.OncoAlert360.com 🚨 This week’s Spotlight is all about trials making waves 🔵 CALYPSO – Savolitinib + durvalumab in papillary renal cancer 🧬 TAILORx – AI validation for breast cancer recurrence prediction 💊 RAGNAR & LUC2001 – Erdafitinib in FGFR-altered cholangiocarcinoma 🟢 RECAST (WJOG9216G) – FOLFIRI vs FOLFOXIRI + ramucirumab in mCRC 🫁 TROPION-Lung02 – Dato-DXd + pembrolizumab in advanced NSCLC 🎯 ORCHARD – Durvalumab + chemo post-osimertinib in EGFR-mutated NSCLC Join nearly 10,000 oncology colleagues — with a 55–60% weekly open rate — and stay up to date with the latest in oncology. @elisabetta_bonzano @eli_agoss @drjosefernandomoura @natalia.gandur @kristina_jankovic @matteo.lambertini @evandretto @esgo.society @agz_eriksson @_i_c_r_o_ @essonews #ELCC26 #EBCC15
#Oncoalert Reel by @oncoalert - The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE Presentation by Dr. Erman Akkus🇹🇷 of Ankara University: How I treat GI Cancers with Limite
682
ON
@oncoalert
The #OncoAlertColloquium 2026 GI Malignancies🚨 DAY THREE Presentation by Dr. Erman Akkus🇹🇷 of Ankara University: How I treat GI Cancers with Limiter Resources REGISTER HERE TO WATCH: https://buff.ly/xwD5G2D A real-world, practice-focused discussion on delivering high-quality care when access is constrained, covering: 🔹 Colorectal & Anal Cancer 🔹 Esophageal & Gastric Cancer 🔹 Hepatocellular Carcinoma 🔹 Pancreatic & Biliary Cancers An important perspective on prioritization, adaptation, and evidence-based decision-making in resource-limited settings. 💡 @barbaramelao_urologia @elisabetta_bonzano @eli_agoss @drjosefernandomoura @natalia.gandur @kristina_jankovic @gaiagriguolo @alizee_c_m @matteo.lambertini @lucarecco @evandretto @maryamlustberg_md
#Oncoalert Reel by @oncoalert - The OncoAlert🚨Newsletter Covering March 12-19, 2026 REGISTER TO GET IT 👉 https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration or
5.9K
ON
@oncoalert
The OncoAlert🚨Newsletter Covering March 12-19, 2026 REGISTER TO GET IT 👉 https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration or www.OncoAlert360.com 🚨 This week’s Spotlight is all about trials making waves 🔬 DESTINY-Breast08 takes center stage — exploring T-DXd combinations in HER2-low mBC with impressive early activity ➕ Also in the mix: 🧬 FOURLIGHT-1 – next-gen CDK4 inhibitor momentum 🍽️ MATTERHORN – perioperative immunotherapy changing GI standards 📩 Plus: cutting-edge science across breast, lung, GI, and GU malignancies Join nearly 10,000 oncology colleagues — with a 55–60% weekly open rate — and stay up to date with the latest in oncology. @elisabetta_bonzano @eli_agoss @drjosefernandomoura @natalia.gandur @kristina_jankovic @matteo.lambertini @evandretto @esgo.society @agz_eriksson @_i_c_r_o_ @essonews
#Oncoalert Reel by @oncoassist - Hear from Dr Akash Maniam as he shares why this ONCO-IQ on Genitourinary cancers, developed in collaboration with @urologysummit , cannot be missed!
323
ON
@oncoassist
Hear from Dr Akash Maniam as he shares why this ONCO-IQ on Genitourinary cancers, developed in collaboration with @urologysummit , cannot be missed! Take the poll question below and access the full quiz here: 🔗Link in Bio🔗 #genitourinary #guoncology #bladdercancer #prostatecancer #oncologyresearch [Oncology Tool, Oncology App, ONCOassist, Oncology Quiz, Gentourinary Cancers Quiz]
#Oncoalert Reel by @onclive - 👀 Watch: Arshed Al-Obeidi, MD, unpacks an analysis of the UC Genome Study focused on the effects alternative splicing on outcomes in metastatic bladd
385
ON
@onclive
👀 Watch: Arshed Al-Obeidi, MD, unpacks an analysis of the UC Genome Study focused on the effects alternative splicing on outcomes in metastatic bladder cancer during the OncLive National Fellows Forum on genitourinary cancers. #oncology #ASCOGU2026
#Oncoalert Reel by @oncoalert - The #OncoAlertColloquium 2026 GU Malignancies🚨 DAY 2 #GU26 Presentation by Dr. Tom Powles: Year in Review in #BladderCancer REGISTER HERE TO WATCH: h
576
ON
@oncoalert
The #OncoAlertColloquium 2026 GU Malignancies🚨 DAY 2 #GU26 Presentation by Dr. Tom Powles: Year in Review in #BladderCancer REGISTER HERE TO WATCH: https://buff.ly/u2B4SNk Tom Powles 2025 year-in-review highlights real progress—and ongoing challenges—in Bladder Cancer @barbaramelao_urologia @elisabetta_bonzano @eli_agoss @drjosefernandomoura @natalia.gandur @kristina_jankovic @gaiagriguolo @alizee_c_m @matteo.lambertini @lucarecco @evandretto @maryamlustberg_md
#Oncoalert Reel by @oncoalert - The #OncoAlertColloquium 2026 GU Malignancies🚨 DAY 2 #GU26 Presentation by Dr. Silke Gillessen 🇨🇭 of APCCC: Year in Review #ProstateCancer REGISTER
773
ON
@oncoalert
The #OncoAlertColloquium 2026 GU Malignancies🚨 DAY 2 #GU26 Presentation by Dr. Silke Gillessen 🇨🇭 of APCCC: Year in Review #ProstateCancer REGISTER HERE TO WATCH: https://buff.ly/FaS5Cb6
#Oncoalert Reel by @oncoalert - The #OncoAlertColloquium 2026 GU Malignancies🚨 #EAU26 Presentation by Dr. Tom Powles: Year in Review in #BladderCancer WATCH HERE👉 https://vimeo.co
484
ON
@oncoalert
The #OncoAlertColloquium 2026 GU Malignancies🚨 #EAU26 Presentation by Dr. Tom Powles: Year in Review in #BladderCancer WATCH HERE👉 https://vimeo.com/1160841460?share=copy&fl=sv&fe=ci Tom Powles 2025 year-in-review highlights real progress—and ongoing challenges—in Bladder Cancer GU Oncology Colloquium Faculty brian_rini 🇺🇸 tompowles1 🇬🇧 declangmurphy 🇦🇺 KidneyCancer🇺🇸 @salvolarosa silkegillessen 🇨🇭 RenuEapen🇦🇺 nataliagandur 🇦🇷 seanmcbride 🇺🇸 DrJaVallejo 🇪🇸 @barbaramelao_urologia @elisabetta_bonzano @eli_agoss @drjosefernandomoura @natalia.gandur @kristina_jankovic @gaiagriguolo @matteo.lambertini @lucarecco @aenizam @gu_cast_podcast @renu.eapen @alvaropintomarin @drenriquegrande @apbello2 @docjavip @mjuanfi81 @kidneycancerassociation @save_therose
#Oncoalert Reel by @oncoalert - Dear Colleagues, OncoAlert 🚨is Proud to be collaborating with @AUC3_Official and will be coming LIVE from Miami🌴 in January for #AUC3 2026 ARTICLE
837
ON
@oncoalert
Dear Colleagues, OncoAlert 🚨is Proud to be collaborating with @AUC3_Official and will be coming LIVE from Miami🌴 in January for #AUC3 2026 ARTICLE HERE: 👉 https://buff.ly/ULensJm Here is one of the co Organizers @DrChoueiri 🇺🇸 To tell us about the #AUC3 publication JUST OUT
#Oncoalert Reel by @oncoalert - Dear Colleagues at #GU26 OncoAlert🚨 is a proud Partner of @AUC3_Official Their Publication is NOW OUT ARTICLE HERE: 👉 https://acsjournals.onlinel
1.0K
ON
@oncoalert
Dear Colleagues at #GU26 OncoAlert🚨 is a proud Partner of @AUC3_Official Their Publication is NOW OUT ARTICLE HERE: 👉 https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70052?utm_campaign=buffer&utm_content=bufferce409&utm_medium=social&utm_source=twitter.com 3⃣Weeks ago We were in Sunny Miami🌴Learning from the TOP oncologists in #KidneyCancer and #BladderPractice . We had a chance to catch up with @DrChoueiri to tell us more about the publication and the meeting. @montyisapal @tiansterzhang @any_necchi @barbaramelao_urologia @drjosefernandomoura @natalia.gandur @kristina_jankovic @choueirit @neerajoncology @auc3_official
#Oncoalert Reel by @gog_foundation - Click link in bio or go to https://ow.ly/138N50YrqwF to view this on demand education today! #clinicaltrials #GOGF #GOGPartners #GynecologicOncology #
227
GO
@gog_foundation
Click link in bio or go to https://ow.ly/138N50YrqwF to view this on demand education today! #clinicaltrials #GOGF #GOGPartners #GynecologicOncology #clinicaltrials #GOGPartners #GOGF #clinicaltrials #endometrialcancer #IGCS2025

✨ Руководство по #Oncoalert

Instagram содержит thousands of публикаций под #Oncoalert, создавая одну из самых ярких визуальных экосистем платформы.

#Oncoalert — один из самых популярных трендов в Instagram прямо сейчас. С более чем thousands of публикаций в этой категории, создатели вроде @oncoalert, @onclive and @oncoassist лидируют со своим вирусным контентом. Просматривайте эти популярные видео анонимно на Pictame.

Что в тренде в #Oncoalert? Самые просматриваемые видео Reels и вирусный контент представлены выше.

Популярные Категории

📹 Видео-тренды: Откройте для себя последние Reels и вирусные видео

📈 Стратегия хэштегов: Изучите трендовые варианты хэштегов для вашего контента

🌟 Избранные Создатели: @oncoalert, @onclive, @oncoassist и другие ведут сообщество

Часто задаваемые вопросы о #Oncoalert

С помощью Pictame вы можете просматривать все реелы и видео #Oncoalert без входа в Instagram. Учетная запись не требуется, ваша активность остается приватной.

Анализ Эффективности

Анализ 12 роликов

✅ Умеренная Конкуренция

💡 Лучшие посты получают в среднем 2.9K просмотров (в 2.2x раз выше среднего)

Публикуйте регулярно 3-5 раз/неделю в активные часы

Советы по Созданию Контента и Стратегия

💡 Лучший контент получает 1K+ просмотров - сосредоточьтесь на первых 3 секундах

📹 Вертикальные видео высокого качества (9:16) лучше всего работают для #Oncoalert - используйте хорошее освещение и четкий звук

✍️ Подробные подписи с историей работают хорошо - средняя длина 532 символов

Популярные поиски по #Oncoalert

🎬Для Любителей Видео

Oncoalert ReelsСмотреть Oncoalert Видео

📈Для Ищущих Стратегию

Oncoalert Трендовые ХэштегиЛучшие Oncoalert Хэштеги

🌟Исследовать Больше

Исследовать Oncoalert